Profusa, Inc., a commercial stage digital health company, announced the successful closing of its business combination with NorthView Acquisition Corp., a special purpose acquisition company. This transaction paves the way for Profusa's common stock to commence trading on Nasdaq under the ticker symbol "PFSA" starting July 14, 2025. The move marks a significant milestone in Profusa's mission to advance its pioneering tissue-integrating biosensors platform, designed for continuous biochemical monitoring and improved chronic disease management. The company expressed excitement about the potential impact of becoming a public entity on its ability to enhance healthcare solutions.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。